EyePoint, Inc. cuts workforce and ends wet AMD trial after clinical setback
What happened
The board of directors at EyePoint, Inc. approved a strategic plan to reduce operating expenses and refocus resources. This plan includes reducing the company's workforce by approximately 53% and concluding the pivotal Phase 3 wet AMD trials early. The decision followed a Phase 3 LUCIA study readout for DURAVYU in wet AMD that did not meet its primary endpoint of non-inferiority, despite meeting several secondary endpoints.
From manilatimes.net
Why it matters
The clinical setback prompted EyePoint, Inc. to preserve capital and maximize shareholder value. The company will now prioritize the use of DURAVYU for diabetic macular edema (DME), with pivotal Phase 3 data expected in the fourth quarter of 2027.
From manilatimes.net
Who's involved
- board of directorsThe board of directors approved the strategic realignment and workforce reduction.
- companyThe company, EyePoint, Inc., is undergoing a strategic pivot following a clinical trial failure.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- companySpeculative
The company might see reduced operating costs due to the approved workforce reduction.
Keep exploring
The entities involved
-
board of directors
group of people who jointly supervise the activities of an organization